US 12,240,869 B2
Inhibitors of cyclin-dependent kinase 7 (CDK7)
Jason J. Marineau, Franklin, MA (US); Michael Bradley, Houston, TX (US); Claudio Chuaqui, Arlington, MA (US); Stephane Ciblat, Montreal (CA); and Anzhelika Kabro, Lachine (CA)
Assigned to Syros Pharmaceuticals, Inc., Cambridge, MA (US)
Appl. No. 17/289,861
Filed by Syros Pharmaceuticals, Inc., Cambridge, MA (US)
PCT Filed Nov. 1, 2019, PCT No. PCT/US2019/059542
§ 371(c)(1), (2) Date Apr. 29, 2021,
PCT Pub. No. WO2020/093011, PCT Pub. Date May 7, 2020.
Claims priority of provisional application 62/927,469, filed on Oct. 29, 2019.
Claims priority of provisional application 62/915,983, filed on Oct. 16, 2019.
Claims priority of provisional application 62/877,189, filed on Jul. 22, 2019.
Claims priority of provisional application 62/754,398, filed on Nov. 1, 2018.
Prior Publication US 2021/0403495 A1, Dec. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07F 9/6558 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/675 (2006.01); A61K 47/26 (2006.01); A61K 47/36 (2006.01); A61K 47/38 (2006.01); A61P 35/00 (2006.01)
CPC C07F 9/65583 (2013.01) [A61K 9/0053 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 31/675 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01); A61K 47/38 (2013.01); A61P 35/00 (2018.01); C07B 2200/05 (2013.01)] 27 Claims
 
1. A compound of structural Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R1 is methyl or ethyl;
R2 is methyl or ethyl;
R3 is 5-methylpiperidin-3-yl, 5,5-dimethylpiperidin-3-yl, 6-methylpiperidin-3-yl, or 6,6-dimethylpiperidin-3-yl, wherein one or more hydrogen atoms in R3 is optionally replaced by deuterium; and
R4 is —CF3 or chloro.